دورية أكاديمية

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

التفاصيل البيبلوغرافية
العنوان: Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
المؤلفون: Brian Ball, Eytan M. Stein
المصدر: Haematologica, Vol 104, Iss 8 (2019)
بيانات النشر: Ferrata Storti Foundation, 2019.
سنة النشر: 2019
المجموعة: LCC:Diseases of the blood and blood-forming organs
مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5
الوصف: Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies that specifically target minimal residual disease are limited. Consensus guidelines on minimal residual disease detection by immunophenotypic and molecular methods are an essential initial step for clinical trials evaluating minimal residual disease. Here, we review promising targets of minimal residual disease prior to allogeneic stem cell transplantation. Specifically, the focus of this review is on the rationale and clinical development of therapies targeting: oncogenic driver mutations, apoptosis, methylation, and leukemic immune targets. We review the progress made in the clinical development of therapies against each target and the challenges that lie ahead.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 0390-6078
1592-8721
Relation: https://haematologica.org/article/view/9000; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721
DOI: 10.3324/haematol.2018.208587
URL الوصول: https://doaj.org/article/9516ab1a18664542b0977b0896f5fd48
رقم الأكسشن: edsdoj.9516ab1a18664542b0977b0896f5fd48
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:03906078
15928721
DOI:10.3324/haematol.2018.208587